October 28, 2011 / 11:25 AM / 7 years ago

Merck profit beats forecast on impressive sales

(Reuters) - Merck & Co’s (MRK.N) quarterly profit and sales beat forecasts as strong demand for the company’s diabetes and asthma drugs offset a sharp decline for its Remicade arthritis drug.

The No. 2 U.S. drugmaker said on Friday it earned $1.69 billion, or 55 cents per share, in the third quarter. That compared with $342 million, or 11 cents per share, in the year-ago period, when the company took several big charges.

Excluding special items, Merck earned 94 cents per share. Analysts on average expected 91 cents per share, according to Thomson Reuters I/B/E/S.

Global revenue rose 8 percent to $12.02 billion, topping Wall Street expectations of $11.61 billion.

Reporting by Ransdell Pierson; Editing by Derek Caney

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below